Search

Jean Bernard Lifetime Achievement Award

The Jean Bernard Lifetime Achievement Award was established in 2008 to honor outstanding physicians and scientists for their lifetime contribution to the advancement of hematology.

Read more

Research

Research in hematology has dramatically improved our understanding of hematologic diseases and resulted in many innovative, groundbreaking discoveries.

Read more

Aging and Hematology

The SWG "Aging and Hematology" has four main goals for the next four years (2019-2023):

To share clinically useful tools in assessing frailty and comorbidities in older adults with hematologic malignancies.

Read more

Tutorial on thalassemia focused on best treatment

Almost 90 delegates from Shiraz and other cities in Iran learned how to identify the best treatment for each thalassemia patient at the EHA-SHRC Hematology Tutorial on Thalassemia on May 10-11, 2018 in Shiraz, Iran.

Read more

SWG Grant-funded projects, 2025

In November and December 2024, SWGs were invited to develop project ideas and apply for a 2025 SWG Grant. For the 2025 call, EHA offered five grants, each worth €30,000.

Read more

Chairs and Members

Chair (2020–2025 term)Prof Raúl Córdoba (Spain)

Vice-chairProf Valentín Goede (Germany)

SWG Executive Board
Sonja Zweegman (The Netherlands)—interest in multiple myeloma
Tamas Fulop (Canada)—interest in geriatrics and immunology
Giuseppe Rossi (Italy)—interest in indolent lymphomas
Dominique Bron (Belgium)—interest in lymphoma, CLL, and cognitive impairment
Sergio Storti (Italy)—interest in aggressive…

Read more

EHA remembers Tessa Holyoake

The Hague, September 2017

We received the sad news of Professor Tessa Holyoake’s passing. Tessa Holyoake was a Professor of Experimental Hematology and the Head of the Paul O'Gorman Leukemia Research Centre.

Read more

Highlights from the SWG

EventsParticipation in the 19th European LeukemiaNet (ELN) SymposiumLocation and dateThis event was held in Mannheim, Germany, on April 18, 2023. Chairs
D. Hoelzer
S. Chiaretti
Topics
Blinatumomab Frontline HOVON Trial (A. Rijneveld, Netherlands). Inotuzumab ozogamicin in MRD+ ALL (G.

Read more